ACT001 reverses resistance of prolactinomas via AMPK-mediated EGR1 and mTOR pathways

Zhu, JH; Tang, C; Cong, ZX; Yuan, F; Cai, XM; Yang, J; Ma, CY

Ma, CY (通讯作者)，Nanjing Univ, Affiliated Jinling Hosp, Dept Neurosurg, Med Sch, Nanjing, Jiangsu, Peoples R China.;Ma, CY (通讯作者)，Southeast Univ, Sch Med, Nanjing, Jiangsu, Peoples R China.

ENDOCRINE-RELATED CANCER, 2022; 29 (2): 33

Abstract

Dopamine agonist (DA) is the first choice for the treatment of prolactinomas, and drug resistance is unavoidable during treatment due to the heterogen......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索